1. Home
  2. MYNZ vs CVKD Comparison

MYNZ vs CVKD Comparison

Compare MYNZ & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYNZ
  • CVKD
  • Stock Information
  • Founded
  • MYNZ 2021
  • CVKD 2022
  • Country
  • MYNZ Germany
  • CVKD United States
  • Employees
  • MYNZ N/A
  • CVKD N/A
  • Industry
  • MYNZ Biotechnology: Pharmaceutical Preparations
  • CVKD Medicinal Chemicals and Botanical Products
  • Sector
  • MYNZ Health Care
  • CVKD Health Care
  • Exchange
  • MYNZ Nasdaq
  • CVKD Nasdaq
  • Market Cap
  • MYNZ 9.8M
  • CVKD 8.2M
  • IPO Year
  • MYNZ 2021
  • CVKD 2023
  • Fundamental
  • Price
  • MYNZ $0.35
  • CVKD $0.45
  • Analyst Decision
  • MYNZ Buy
  • CVKD Strong Buy
  • Analyst Count
  • MYNZ 2
  • CVKD 2
  • Target Price
  • MYNZ $3.00
  • CVKD $3.50
  • AVG Volume (30 Days)
  • MYNZ 1.4M
  • CVKD 72.2K
  • Earning Date
  • MYNZ 08-13-2024
  • CVKD 08-12-2024
  • Dividend Yield
  • MYNZ N/A
  • CVKD N/A
  • EPS Growth
  • MYNZ N/A
  • CVKD N/A
  • EPS
  • MYNZ N/A
  • CVKD N/A
  • Revenue
  • MYNZ $895,479.00
  • CVKD N/A
  • Revenue This Year
  • MYNZ $67.40
  • CVKD N/A
  • Revenue Next Year
  • MYNZ $191.13
  • CVKD N/A
  • P/E Ratio
  • MYNZ N/A
  • CVKD N/A
  • Revenue Growth
  • MYNZ 69.00
  • CVKD N/A
  • 52 Week Low
  • MYNZ $0.32
  • CVKD $0.36
  • 52 Week High
  • MYNZ $4.71
  • CVKD $2.17
  • Technical
  • Relative Strength Index (RSI)
  • MYNZ 39.09
  • CVKD 48.55
  • Support Level
  • MYNZ $0.34
  • CVKD $0.43
  • Resistance Level
  • MYNZ $0.46
  • CVKD $0.49
  • Average True Range (ATR)
  • MYNZ 0.07
  • CVKD 0.02
  • MACD
  • MYNZ 0.00
  • CVKD -0.00
  • Stochastic Oscillator
  • MYNZ 10.83
  • CVKD 39.47

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

Share on Social Networks: